NYSE · LLY
Eli Lilly and Company
$1,420.82+$47.12 (+3.43%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
Loading market information…
OTC · UTRS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Minerva Surgical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Minerva Surgical, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$8.81. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Minerva Surgical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Minerva Surgical, Inc. functions as a commercial-stage medical technology enterprise, specializing in the creation, production, and distribution of innovative, minimally invasive solutions tailored to address the uterine healthcare needs of women throughout the United States. Their suite of offerings features advanced endometrial ablation systems, including the Minerva ES and Genesys HTA. They also provide the Symphion Tissue Removal System, a sophisticated, minimally invasive device for uterine tissue removal that uniquely integrates bladeless tissue resection, coagulation capabilities, continuous visualization during procedures, and precise intrauterine pressure monitoring. Additionally, the Resectr Tissue Resection Device is a handheld surgical tool engineered for the hysteroscopic removal and diagnostic evaluation of endometrial polyps. These specialized instruments are utilized by obstetrician-gynecologists across a variety of clinical settings, such as hospitals, outpatient ambulatory surgical centers, and private physician practices. The company was founded in 2008 and is headquartered in Santa Clara, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:45 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Aug 9, 2022 | -$4.00+41.18% vs estimate | $12.97M |
|---|
| Q1 2022 | May 11, 2022 | -$7.60-22.58% vs estimate | $10.94M+1.53% vs estimate |
|---|
| Q4 2021 | Mar 8, 2022 | -$0.26+10.34% vs estimate | $13.65M+25.76% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,420.82+$47.12 (+3.43%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$1.60-$0.22 (-12.08%)
SCWorx Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.65% below the high.
$1.95-$0.02 (-1.02%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.17% below the high.
$0.81-$0.03 (-3.16%)
Dermata Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.52% below the high.
$1.04-$0.06 (-5.45%)
Akanda Corp.’s quoted price sits in the lower half of its reported 52-week range, 98.68% below the high.
$1.76+$0.03 (+1.73%)
TransCode Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.03% below the high.
$0.06+$0.00 (+2.0%)
FOXO Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.15% below the high.
$0.00$0.00 (0.0%)
Etao International Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
